Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment interruption for convenience, cost cutting and toxicity sparing

Treatment interruption for convenience, cost cutting and toxicity sparing Treatment interruption for convenience, cost cutting and toxicity sparing a b Reto Nu ¨ esch and Bernhard Hirschel Purpose of review Introduction Scheduled treatment interruption appears to be an Despite the highly beneficial effect of antiretroviral attractive alternative to continuous treatment in reducing therapy (ART) on the mortality and morbidity of HIV side effects and costs and increasing comfort and quality of infection [1 – 5], its long-term success is challenged by life by reducing overall drug exposure. The question is the many problems inherent in life-long therapy. The whether such an interruption is safe. The development of perspective of never-ending pill ingestion is dispiriting resistance, treatment failure, and the occurrence of to many patients, leading to treatment fatigue with possible diseases induced by decreasing CD4 cell counts or negative effects on adherence [6 – 8]. Drug toxicity is a well virological rebound are matters of concern. recognized problem in industrialized and developing Recent findings countries alike [9 – 15,16 ], and the costs of treating millions Fixed-cycle scheduled treatment interruption and CD4 cell- are challenging healthcare systems worldwide. These guided treatment interruption have been evaluated in issues will become ever more urgent with increased access randomized controlled trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Treatment interruption for convenience, cost cutting and toxicity sparing

Current Opinion in HIV and Aids , Volume 2 (1) – Jan 1, 2007

Loading next page...
 
/lp/wolters-kluwer-health/treatment-interruption-for-convenience-cost-cutting-and-toxicity-sRTOoHW3Ri

References (75)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e328011a1df
pmid
19372863
Publisher site
See Article on Publisher Site

Abstract

Treatment interruption for convenience, cost cutting and toxicity sparing a b Reto Nu ¨ esch and Bernhard Hirschel Purpose of review Introduction Scheduled treatment interruption appears to be an Despite the highly beneficial effect of antiretroviral attractive alternative to continuous treatment in reducing therapy (ART) on the mortality and morbidity of HIV side effects and costs and increasing comfort and quality of infection [1 – 5], its long-term success is challenged by life by reducing overall drug exposure. The question is the many problems inherent in life-long therapy. The whether such an interruption is safe. The development of perspective of never-ending pill ingestion is dispiriting resistance, treatment failure, and the occurrence of to many patients, leading to treatment fatigue with possible diseases induced by decreasing CD4 cell counts or negative effects on adherence [6 – 8]. Drug toxicity is a well virological rebound are matters of concern. recognized problem in industrialized and developing Recent findings countries alike [9 – 15,16 ], and the costs of treating millions Fixed-cycle scheduled treatment interruption and CD4 cell- are challenging healthcare systems worldwide. These guided treatment interruption have been evaluated in issues will become ever more urgent with increased access randomized controlled trials.

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Jan 1, 2007

There are no references for this article.